While the present results may present microglia as a therapeutic target, a treatment trial with minocycline failed to rectify the elevated TSPO-PET binding in a cohort of patients with treatment-resistant depression (Attwells et al., 2021). This evidence concerns the gene TSPO and major depressive disorder.